B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma [Phase 1, Phase 2]
This clinical trial update notes that Kite is recruiting participants for a Phase 1/Phase 2 study of KITE-363 or KITE-753 in relapsed and/or…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment [Phase 1]
Phase 1 trial evaluating safety of INT2104 infusions in adults with B-cell cancers, including B-cell non-Hodgkin lymphoma and precursor B-ce…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
This ClinicalTrials.gov entry reports a Phase 1/2 study evaluating selinexor with ICE chemotherapy for B-cell non-Hodgkin lymphoma with seco…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia [EARLY_Phase 1]
A Phase 1 clinical trial evaluating the safety and efficacy of GT801 Injection in adults with relapsed/refractory CD19-positive B-cell hemat…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial update evaluating epcoritamab in combination with dose-adjusted EPOCH-R for aggressive B-cell non-Hodgkin lymphoma;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL [Phase 1, Phase 2]
This clinical trial update notes the ongoing Phase 1/2 study of UCD19 CAR-T cell therapy in pediatric patients with B-cell acute lymphoblast…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: CAR T-cell Therapy in Patients With Renal Dysfunction [Phase 2]
A Phase 2 clinical trial evaluating CAR T-cell therapy in patients with renal dysfunction is currently recruiting for indications including …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating ONC-PluReceptor NK cells in combination with epcoritamab and tafasitamab for patients with recurren…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma [Phase 1]
A Phase 1 trial assessing safety and potential efficacy of Iberdomide (CC-220) and CC-99282 in combination with R-CHOP for B-cell non-Hodgki…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma [Phase 1]
Phase 1 clinical trial update examining pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma [Phase 1]
A Phase 1 clinical trial evaluating the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and in combination with ipilimumab, nivolumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial is evaluating the combination of nivolumab with ASTX727 (decitabine/cedazuridine) in relapsed or refractory B-cell …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial evaluating adaptive dual-target CAR-T cell therapy for relapsed or refractory hematologic malignancies; recru…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma [Phase 1]
Phase 1 clinical trial evaluating a three-drug regimen (alisertib, bortezomib, and rituximab) in patients with relapsed or refractory mantle…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) [Phase 1]
This is a Phase 1 trial update evaluating JNJ-80948543 in combination with other CD3 T-cell engagers for relapsed or refractory B-cell non-H…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) [Phase 1]
A Phase 1 study of JNJ-90009530 for relapsed or refractory B-cell non-Hodgkin lymphoma is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study update for JNJ-88998377 in relapsed/refractory B-cell non-Hodgkin lymphoma; the trial is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma [Phase 1, Phase 2]
A phase 1/2 dose-escalation trial evaluating glofitamab as a single agent and in combination with obinutuzumab after a fixed pre-treatment d…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase I/II clinical trial of AZD4512 as monotherapy or with anticancer agents in relapsed/refractory B-cell non-Hodgkin lymphoma, currently …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [EARLY_Phase 1]
A Phase I/IIa open-label trial evaluating IMV101 as a single agent for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiti…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma [NA]
Clinical trial update for LIBERTY, a study using liquid biopsy to diagnose and monitor CNS involvement in high-risk B-cell non-Hodgkin lymph…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas [Phase 1]
A Phase 1 trial is evaluating the safety of REGN5837 in combination with odronextamab for adults with aggressive B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL [Phase 1, Phase 2]
This clinical trials update describes a phase 1/2 study of a CD19 CAR T-cell therapy with CD34 selection for patients with CD19-positive rel…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma
An active clinical trial investigates dynamic monitoring of plasma circulating tumor DNA to prognosticate outcomes in patients with B-cell n…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating PIT565 in relapsed/refractory B-cell malignancies, including B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphobla…